Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB

Ratings ESG MSCI

Ratings Sarepta Therapeutics, Inc.: Strengths and Weaknesses

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Highlights: Sarepta Therapeutics, Inc.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Analyst opinion has improved significantly over the past four months.
  • The group usually releases upbeat results with huge surprise rates.
Weaknesses: Sarepta Therapeutics, Inc.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • With a 2025 P/E ratio at -4.34 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • Based on current prices, the company has particularly high valuation levels.
  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Most analysts recommend that the stock should be sold or reduced.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Rating Financials

Sarepta Therapeutics, Inc. SectorUnited States
Fundamentals
Growth
Revenue growth
EPS growth
FCF growth
Profitability
EBITDA Margin
EBIT Margin
Net Margin
Capital Efficiency
ROA
ROCE
ROE
Financial Health
Gearing
Leverage
Capital Intensity
Balance sheet growth
Long Term balance sheet growth
Long term revenue growth
Long term EPS growth
More ratings

Rating Valuation

Sarepta Therapeutics, Inc. SectorUnited States
Global Valuation
Enterprise value
EV/Revenue
EV/EBITDA
EV/FCF-
Equity Valuation
P/E
PBR
Dividend Yield-
EV/EBIT
CAPEX/Revenue
More ratings

Rating Consensus

Sarepta Therapeutics, Inc. SectorUnited States
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (1 year)
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (1 year)
Analysts' target price evolution (4 months)
Analysts' recommendations evolution (7 days)
Target Price evolution (7 days)
More ratings

Rating Business Predictability

Sarepta Therapeutics, Inc. SectorUnited States
Visibility
Analysts' coverage
Financial estimates divergence
Analysts' recommendations divergence
Analysts' Target price divergence
Surprise rates

Rating Revisions

Sarepta Therapeutics, Inc. SectorUnited States
Financial revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
EPS revisions (1 year)
EPS revisions (4 months)
EPS revisions (7 days)
Revenue revisions (7 days)
More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
249.71Cr
BBB
216.78Cr -
BB
- -
37Cr - - - - - - -
7.59Cr - - - - - - -
Average 127.82Cr
BBB
Weighted average by Cap.
BBB
See all sector ratings
  1. Stock Market
  2. Equities
  3. SRPT Stock
  4. Ratings Sarepta Therapeutics, Inc.